Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
0.3240
+0.0070 (2.21%)
At close: Jul 16, 2025, 4:00 PM
0.3265
+0.0025 (0.77%)
Pre-market: Jul 17, 2025, 7:15 AM EDT

Plus Therapeutics Stock Forecast

PSTV's stock price has decreased by -81.69% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 3 analysts that cover Plus Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $10.83, which forecasts a 3242.59% increase in the stock price over the next year. The lowest target is $3 and the highest is $20.5.

Price Target: $10.83 (+3242.59%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$3.00$10.83$9.00$20.5
Change+825.93%+3242.6%+2677.8%+6227.2%

Analyst Ratings

The average analyst rating for Plus Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingFeb '25Mar '25Apr '25May '25Jun '25Jul '25
Strong Buy233222
Buy000000
Hold000111
Sell000000
Strong Sell000000
Total233333

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Maintains
$5.5$3
Strong BuyMaintains$5.5$3+825.93%Jun 27, 2025
D. Boral Capital
D. Boral Capital
Hold
Maintains
$9
HoldMaintains$9+2,677.78%Jun 25, 2025
Ascendiant Capital
Ascendiant Capital
Strong Buy
Maintains
$20$21
Strong BuyMaintains$20$21+6,227.16%Jun 5, 2025
D. Boral Capital
D. Boral Capital
Hold
Downgrades
n/a
HoldDowngradesn/an/aMay 5, 2025
Ascendiant Capital
Ascendiant Capital
Strong Buy
Maintains
$19$20
Strong BuyMaintains$19$20+6,072.84%Apr 21, 2025
More Analyst Ratings

Financial Forecast

Revenue This Year
6.65M
from 5.82M
Increased by 14.10%
Revenue Next Year
7.17M
from 6.65M
Increased by 7.96%
EPS This Year
-0.81
from -2.34
EPS Next Year
-0.56
from -0.81
Fiscal YearFY 2020FY 2021FY 2022FY 2023FY 2024FY 2025FY 2026FY 2027
Period EndingDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026Dec 31, 2027
Revenue
303.00K-224.00K4.91M5.82M6.65M7.17M33.86M
Revenue Growth
-95.67%--2,093.30%18.54%14.10%7.96%372.00%
EPS
-27.92-16.65-11.58-4.24-2.34-0.81-0.56-0.26
EPS Growth
--------
Forward PE
--------
No. Analysts
-----554
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue20252026202720282029
High10.8M12.7M57.0M
Avg6.6M7.2M33.9M
Low4.2M3.9M16.9M

Revenue Growth

Revenue Growth20252026202720282029
High
85.8%
91.2%
695.1%
Avg
14.1%
8.0%
372.0%
Low
-28.7%
-41.0%
135.8%

EPS Forecast

EPS20252026202720282029
High-0.58-0.29-0.17
Avg-0.81-0.56-0.26
Low-0.98-0.96-0.33

EPS Growth

EPS Growth20252026202720282029
High---
Avg---
Low---
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.